Leerink analyst David Risinger upgraded Bristol Myers (BMY) to Outperform from Market Perform with a price target of $73, up from $55. The firm expects “upward pressure” on Cobenfy and milvexian consensus expectations to drive stock outperformance from current levels. In the wake of AbbVie’s (ABBV) emraclidine pivotal Phase 2 trial failures, Leerink no longer anticipates that competing product to launch in 2026. As such, it significantly boosted its long-term Cobenfy projections, including 2030 sales up 36% from $4.2B to $5.7B. The analyst sees the potential for peak Cobenfy sales of over $10B if it succeeds in additional indications. Leerink also increased our milvexian sales projections after further contemplating the positive trial update announced on Bristol’s Q3 call.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BMY:
- Bristol Myers price target raised to $60 from $55 at Citi
- Bristol Myers upgraded to Outperform from Market Perform at Leerink
- Evercore says failure of emraclidine ‘may’ be ‘substantial’ Neurocrine positive
- AbbVie under pressure as schizophrenia drug fails two trials
- Leerink sees AbbVie’s trial results as ‘clear positive’ for Bristol Myers
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
